Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is discussed as a potential hair loss treatment, with doubts about its effectiveness and availability. Users mention using finasteride and minoxidil, and express concerns about PP405's cost and market release.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

User discusses verteporfin for hair regrowth through "super microneedling" and preventing scarring. They mention a case of an old man regrowing hair after a head injury and suggest verteporfin could recreate this result.

The conversation is about the delay in receiving updates on the HMI-115 phase 1 trial for hair loss. No specific treatments are mentioned in the conversation.

A 21-year-old has been using a 0.5 mm dermaroller weekly with 5% Minoxidil for five months and Finasteride for three months to address hair loss. The conversation includes questions about the frequency of dermarolling.

Hair loss discussion mentions HMI-115 efficacy in 3 months after Phase II study. Users discuss treatment effectiveness and mention massive regrowth in previously bald areas.

The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.

A user has been using finasteride since 2018, switched to dutasteride, and added minoxidil, microneedling, and a tretinoin/spiro compound. They are pleased with the results and hopeful for more improvement.

PP405 is a promising new hair loss treatment that may reactivate dormant hair follicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.

User had minor hair transplant in 2020, used Fin since 2008, Min since 2014, and added microneedling in 2022. Routine was irregular with no severe effects.

RepliCel has purchased Trichoscience, and they have a video about hair multiplication. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.

A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.

A 22-year-old trans woman has been on 6mg estradiol enanthate for five months. She reports thicker and healthier hair but not much regrowth yet.

The conversation is about the quality of RU58841 powder from Shaanxi Laon Biotech. The user is inquiring if anyone has experience with this product.

A 27-year-old has seen hair regrowth over 5 months using 2ml of 5% minoxidil daily, 50mg of RU58841 daily, and occasional microneedling. Commenters think the results are good and ask about microneedling frequency, needle size, and if ketoconazole shampoo is used.

AnagenInc is ready to produce a hair loss treatment called GT20029 if there is enough demand. People are discussing combining it with other treatments like finasteride and minoxidil, and some are concerned about the legitimacy and safety of gray market products.

A user's progress with hair loss treatments over 5 months, using topical finasteride (0.3%) and minoxidil (6%), as well as weekly microneedling sessions; other users have asked questions about the results and offered compliments.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.

A 26-year-old man shared his positive results after 10 months of treating male pattern baldness using a regimen that includes Estradiol Enanthate, DHPA, Bicalutamide, Dutasteride, oral and topical Minoxidil, and a dermaroller. He experienced mild gynecomastia and reduced body hair as side effects but was satisfied with the outcome.

The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.

A 21-year-old male diagnosed with telogen effluvium and male pattern baldness started oral finasteride, which initially slowed hair loss and slightly thickened hair, but experienced increased shedding after surgery. The doctor recommended iron and vitamin D supplements, and the user is seeking additional advice.

The user experienced hair regrowth and improved hair density using oral finasteride and topical minoxidil, with microneedling as an additional treatment. They are considering a hair transplant for low-density areas but are uncertain due to existing follicles.

The user shared their 5-year hair recovery journey using finasteride, RU58841, dutasteride, minoxidil, and microneedling, noting mixed progress but overall improvement. They regret not starting treatment earlier and recently received positive health feedback from their doctor.

A human trial involving the use of Verteporfin as a treatment for hair loss, which has been ongoing for 119 days with an update on its progress. Treatments such as Minoxidil, Finasteride and RU58841 have also been discussed.

The user stopped using finasteride and RU58841 and is considering CB-03-01 for androgenic alopecia but is concerned about the cost and effectiveness, especially at a lower dose than in clinical trials. They are also using minoxidil, micro-needling, and nizoral shampoo but are unsure about the correct application method for CB-03-01.

The conversation is about using Verteporfin with microneedling as a potential hair loss treatment that may regenerate hair follicles with minimal scarring. There are concerns about the optimal dosage and the DHT sensitivity of the new follicles.

Doctors are testing verteporfin topically for healing and potential regeneration after transplants. The user is asking how it is formulated for topical use, such as if it's mixed with a carrier gel.

Combining microneedling with Low Level Laser Therapy (LLLT) for hair growth, with discussions on device legitimacy and effectiveness. Alternatives like PEMF and the use of oral and topical treatments such as dutasteride, minoxidil, and finasteride are also considered.

Rhamnose may promote hair growth and pigmentation, suggesting it as a potential hair loss treatment. The conversation discusses its potential alongside known treatments like Minoxidil, finasteride, and RU58841.